Lactate dehydrogenase, creatinine kinase predict survival, poor prognosis in lung cancer
Similar to their role in other cancers, plasma concentrations of lactate dehydrogenase (LDH) and creatinine kinase (CK) are independent predictors of survival and poor prognosis in lung cancer patients, particularly those with adenocarcinoma, a new study reveals.
The study included 1,142 lung cancer patients (69.2 percent male), of which 678 were positive for CK and 464 were negative, with respect to cut-off values. In comparison, 410 were LDH positive and 732 were negative.
In lung adenocarcinoma patients (n=608), bone metastasis was significantly more common in CK-negative than in CK-positive patients (27.6 vs 19.4 percent; p<0.05), while a stage four disease was significantly more common in in LDH-positive than in LDH-negative patients (72.5 vs 57.2 percent; p<0.05).
Elevated LDH levels were also significantly associated with metastasis to the bone (p<0.001), liver (p<0.001) and adrenal gland (p<0.001).
On the other hand, squamous cell carcinoma patients (n=307) that were positive for CK showed lower bone metastasis compared to those who were negative (6.8 vs 16.8 percent). Metastasis to other regions was not related to CK levels. LDH level was not significantly associated with any of the clinical characteristics.
In all lung cancer patients, lower plasma CK was associated with significantly poorer overall survival status (p<0.001), while higher LDH levels were linked to significantly poorer outcomes (p<0.001).
In those with adenocarcinoma, lower CH and higher LDH were associated with poor survival status (p<0.001 for both), while in squamous cell carcinoma patients, only CK concentration was tied to survival (p<0.05).